GR1002180B - Method for preventing the reproduction of virus in mammals cells by using protein conjugates of a monoclonic antibody antivirus - Google Patents

Method for preventing the reproduction of virus in mammals cells by using protein conjugates of a monoclonic antibody antivirus

Info

Publication number
GR1002180B
GR1002180B GR900100550A GR900100550A GR1002180B GR 1002180 B GR1002180 B GR 1002180B GR 900100550 A GR900100550 A GR 900100550A GR 900100550 A GR900100550 A GR 900100550A GR 1002180 B GR1002180 B GR 1002180B
Authority
GR
Greece
Prior art keywords
antivirus
virus
reproduction
preventing
protein conjugates
Prior art date
Application number
GR900100550A
Other languages
English (en)
Other versions
GR900100550A (el
Inventor
Mintzer Joyce Zarling
Fatih M Uckun
Original Assignee
Oncogen
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen, Univ Minnesota filed Critical Oncogen
Publication of GR900100550A publication Critical patent/GR900100550A/el
Publication of GR1002180B publication Critical patent/GR1002180B/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GR900100550A 1989-07-25 1990-07-18 Method for preventing the reproduction of virus in mammals cells by using protein conjugates of a monoclonic antibody antivirus GR1002180B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (2)

Publication Number Publication Date
GR900100550A GR900100550A (el) 1991-12-10
GR1002180B true GR1002180B (en) 1996-03-11

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100550A GR1002180B (en) 1989-07-25 1990-07-18 Method for preventing the reproduction of virus in mammals cells by using protein conjugates of a monoclonic antibody antivirus

Country Status (17)

Country Link
EP (1) EP0441917B1 (el)
JP (1) JP3109678B2 (el)
KR (1) KR920700698A (el)
AT (1) ATE137410T1 (el)
AU (1) AU631674B2 (el)
CA (1) CA2037900C (el)
DE (1) DE69026812T2 (el)
DK (1) DK0441917T3 (el)
ES (1) ES2087158T3 (el)
FI (1) FI911447A0 (el)
GR (1) GR1002180B (el)
IE (1) IE74143B1 (el)
IL (1) IL95134A (el)
NO (1) NO911174L (el)
NZ (1) NZ234607A (el)
PT (1) PT94789B (el)
WO (1) WO1991001145A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (el) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives

Also Published As

Publication number Publication date
ATE137410T1 (de) 1996-05-15
NO911174D0 (no) 1991-03-22
JPH04502625A (ja) 1992-05-14
PT94789A (pt) 1991-03-20
DE69026812T2 (de) 1996-11-28
DK0441917T3 (da) 1996-09-16
IL95134A (en) 1996-01-31
FI911447A0 (fi) 1991-03-25
AU631674B2 (en) 1992-12-03
NZ234607A (en) 1992-10-28
JP3109678B2 (ja) 2000-11-20
EP0441917A1 (en) 1991-08-21
NO911174L (no) 1991-05-24
IL95134A0 (en) 1991-06-10
WO1991001145A1 (en) 1991-02-07
EP0441917B1 (en) 1996-05-01
AU6140590A (en) 1991-02-22
DE69026812D1 (de) 1996-06-05
KR920700698A (ko) 1992-08-10
PT94789B (pt) 1997-04-30
IE74143B1 (en) 1997-07-02
CA2037900C (en) 1999-11-16
CA2037900A1 (en) 1991-01-26
ES2087158T3 (es) 1996-07-16
IE902593A1 (en) 1991-02-27
GR900100550A (el) 1991-12-10

Similar Documents

Publication Publication Date Title
NO881491D0 (no) Fremgangsmaate ved dyrking av leukocyter.
FI930256A (fi) Substituerade bicykliska bis-arylfoereningar med selektiv antagonistiskaktivitet mot leukotrien b4, framstaellning och anvaendning daerav i farmaceutiska kompositioner
IT8921515A0 (it) Procedimento per la preparazione di estratti ad alto contenuto in antocianosidi.
NO891711D0 (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
AU634518B2 (en) Hepatitis B core antigen conjugates
DE68905886D1 (de) Calcitoninzusammensetzung zur intranasalen verabreichung.
DE69014175D1 (de) Magnetooptische Wiedergabemethode.
DE68915515T2 (de) Zweiseitiges Kopiersystem mit hybrider Aufstapelung.
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
NO891194D0 (no) Transportprosess/separasjonsprosess.
DE68916759D1 (de) Hybridfolgen-Dokumentenkopiervorrichtung.
GR1002180B (en) Method for preventing the reproduction of virus in mammals cells by using protein conjugates of a monoclonic antibody antivirus
PT553667E (pt) Receptor do ldl soluvel sua producao e utilizacao
DK528279A (da) Fremgangsmaade til isolering af hepatitis b e antigen eller antistof
FI893243A0 (fi) Foerfarande och anordning foer kromatografisk separation.
NO881635D0 (no) Vinylsubstituerte radioaktive halogenkonjugater for proteinmerking.
AU4070289A (en) Monoclonal antibody for inhibiting cell infection by hiv viruses
DE3877474D1 (de) Polyetherimid-harz-zusammensetzung.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.
IT8720284A0 (it) Tavola d'appoggio in particolareper copiatrici.
ATE219512T1 (de) Rinderovarzellinie (frov) zur virusvermehrung
IT8730615V0 (it) Gruppo di preriscaldamento e polverizzazione particolarmente per nafta.
ITTO910901A1 (it) Procedimento per l'incollaggio di pezzi di lamiera.
IE880242L (en) Hepatitis b virus antigens.
KR900010574U (ko) 키 보드(Key Board)용 스위칭(Switching) 필름(Film)

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees